nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—HTR2A—vein—ovarian cancer	0.0123	0.128	CbGeAlD
Duloxetine—NPY1R—myometrium—ovarian cancer	0.0119	0.123	CbGeAlD
Duloxetine—NPY1R—uterine cervix—ovarian cancer	0.00924	0.096	CbGeAlD
Duloxetine—NPY1R—gonad—ovarian cancer	0.00775	0.0806	CbGeAlD
Duloxetine—NPY1R—female reproductive system—ovarian cancer	0.00692	0.0719	CbGeAlD
Duloxetine—NPY1R—vagina—ovarian cancer	0.00626	0.0651	CbGeAlD
Duloxetine—NPY1R—testis—ovarian cancer	0.00559	0.0581	CbGeAlD
Duloxetine—NPY1R—lymph node—ovarian cancer	0.00405	0.0421	CbGeAlD
Duloxetine—SLC6A2—decidua—ovarian cancer	0.00299	0.0311	CbGeAlD
Duloxetine—HTR2C—female reproductive system—ovarian cancer	0.00282	0.0293	CbGeAlD
Duloxetine—SLC6A4—female reproductive system—ovarian cancer	0.00267	0.0277	CbGeAlD
Duloxetine—SLC6A2—gonad—ovarian cancer	0.00263	0.0273	CbGeAlD
Duloxetine—SLC6A3—testis—ovarian cancer	0.00235	0.0244	CbGeAlD
Duloxetine—SLC6A2—female reproductive system—ovarian cancer	0.00235	0.0244	CbGeAlD
Duloxetine—HTR2A—embryo—ovarian cancer	0.00233	0.0242	CbGeAlD
Duloxetine—HTR2A—epithelium—ovarian cancer	0.0019	0.0198	CbGeAlD
Duloxetine—SLC6A2—testis—ovarian cancer	0.0019	0.0197	CbGeAlD
Duloxetine—HTR2A—gonad—ovarian cancer	0.00158	0.0164	CbGeAlD
Duloxetine—HTR2A—female reproductive system—ovarian cancer	0.00141	0.0147	CbGeAlD
Duloxetine—SLC6A2—lymph node—ovarian cancer	0.00137	0.0143	CbGeAlD
Duloxetine—CYP2D6—female reproductive system—ovarian cancer	0.00129	0.0134	CbGeAlD
Duloxetine—HTR2A—vagina—ovarian cancer	0.00128	0.0133	CbGeAlD
Duloxetine—CYP2D6—female gonad—ovarian cancer	0.00117	0.0122	CbGeAlD
Duloxetine—HTR2A—testis—ovarian cancer	0.00114	0.0118	CbGeAlD
Duloxetine—CYP2D6—testis—ovarian cancer	0.00104	0.0108	CbGeAlD
Duloxetine—Jaundice—Epirubicin—ovarian cancer	0.000499	0.000605	CcSEcCtD
Duloxetine—Stomatitis—Epirubicin—ovarian cancer	0.000499	0.000605	CcSEcCtD
Duloxetine—Urinary tract infection—Epirubicin—ovarian cancer	0.000497	0.000603	CcSEcCtD
Duloxetine—Conjunctivitis—Epirubicin—ovarian cancer	0.000497	0.000603	CcSEcCtD
Duloxetine—Dysuria—Doxorubicin—ovarian cancer	0.000496	0.000602	CcSEcCtD
Duloxetine—Decreased appetite—Paclitaxel—ovarian cancer	0.000496	0.000602	CcSEcCtD
Duloxetine—Dry mouth—Docetaxel—ovarian cancer	0.000494	0.000599	CcSEcCtD
Duloxetine—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.000493	0.000598	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000493	0.000598	CcSEcCtD
Duloxetine—Fatigue—Paclitaxel—ovarian cancer	0.000492	0.000597	CcSEcCtD
Duloxetine—Pollakiuria—Doxorubicin—ovarian cancer	0.00049	0.000595	CcSEcCtD
Duloxetine—Pain—Paclitaxel—ovarian cancer	0.000488	0.000592	CcSEcCtD
Duloxetine—Constipation—Paclitaxel—ovarian cancer	0.000488	0.000592	CcSEcCtD
Duloxetine—Confusional state—Docetaxel—ovarian cancer	0.000488	0.000592	CcSEcCtD
Duloxetine—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.000485	0.000588	CcSEcCtD
Duloxetine—Hepatobiliary disease—Epirubicin—ovarian cancer	0.000484	0.000587	CcSEcCtD
Duloxetine—Oedema—Docetaxel—ovarian cancer	0.000484	0.000587	CcSEcCtD
Duloxetine—Anaphylactic shock—Docetaxel—ovarian cancer	0.000484	0.000587	CcSEcCtD
Duloxetine—Weight increased—Doxorubicin—ovarian cancer	0.000483	0.000586	CcSEcCtD
Duloxetine—Epistaxis—Epirubicin—ovarian cancer	0.000483	0.000585	CcSEcCtD
Duloxetine—Infection—Docetaxel—ovarian cancer	0.000481	0.000583	CcSEcCtD
Duloxetine—Weight decreased—Doxorubicin—ovarian cancer	0.00048	0.000583	CcSEcCtD
Duloxetine—Hyperglycaemia—Doxorubicin—ovarian cancer	0.000479	0.000581	CcSEcCtD
Duloxetine—Shock—Docetaxel—ovarian cancer	0.000476	0.000577	CcSEcCtD
Duloxetine—Nervous system disorder—Docetaxel—ovarian cancer	0.000474	0.000575	CcSEcCtD
Duloxetine—Thrombocytopenia—Docetaxel—ovarian cancer	0.000474	0.000574	CcSEcCtD
Duloxetine—Infestation NOS—Doxorubicin—ovarian cancer	0.000473	0.000574	CcSEcCtD
Duloxetine—Infestation—Doxorubicin—ovarian cancer	0.000473	0.000574	CcSEcCtD
Duloxetine—Tachycardia—Docetaxel—ovarian cancer	0.000472	0.000573	CcSEcCtD
Duloxetine—Feeling abnormal—Paclitaxel—ovarian cancer	0.00047	0.00057	CcSEcCtD
Duloxetine—Skin disorder—Docetaxel—ovarian cancer	0.00047	0.00057	CcSEcCtD
Duloxetine—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	0.000469	0.000569	CcSEcCtD
Duloxetine—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000467	0.000566	CcSEcCtD
Duloxetine—Renal failure—Doxorubicin—ovarian cancer	0.000465	0.000564	CcSEcCtD
Duloxetine—Haemoglobin—Epirubicin—ovarian cancer	0.000462	0.00056	CcSEcCtD
Duloxetine—Stomatitis—Doxorubicin—ovarian cancer	0.000461	0.00056	CcSEcCtD
Duloxetine—Jaundice—Doxorubicin—ovarian cancer	0.000461	0.00056	CcSEcCtD
Duloxetine—Anorexia—Docetaxel—ovarian cancer	0.000461	0.000559	CcSEcCtD
Duloxetine—Urinary tract infection—Doxorubicin—ovarian cancer	0.00046	0.000558	CcSEcCtD
Duloxetine—Conjunctivitis—Doxorubicin—ovarian cancer	0.00046	0.000558	CcSEcCtD
Duloxetine—Haemorrhage—Epirubicin—ovarian cancer	0.000459	0.000557	CcSEcCtD
Duloxetine—Hepatitis—Epirubicin—ovarian cancer	0.000459	0.000557	CcSEcCtD
Duloxetine—Hypoaesthesia—Epirubicin—ovarian cancer	0.000457	0.000554	CcSEcCtD
Duloxetine—Pharyngitis—Epirubicin—ovarian cancer	0.000456	0.000553	CcSEcCtD
Duloxetine—Urinary tract disorder—Epirubicin—ovarian cancer	0.000454	0.00055	CcSEcCtD
Duloxetine—Urticaria—Paclitaxel—ovarian cancer	0.000453	0.00055	CcSEcCtD
Duloxetine—Oedema peripheral—Epirubicin—ovarian cancer	0.000452	0.000549	CcSEcCtD
Duloxetine—Connective tissue disorder—Epirubicin—ovarian cancer	0.000451	0.000547	CcSEcCtD
Duloxetine—Body temperature increased—Paclitaxel—ovarian cancer	0.000451	0.000547	CcSEcCtD
Duloxetine—Abdominal pain—Paclitaxel—ovarian cancer	0.000451	0.000547	CcSEcCtD
Duloxetine—Urethral disorder—Epirubicin—ovarian cancer	0.00045	0.000546	CcSEcCtD
Duloxetine—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.000448	0.000543	CcSEcCtD
Duloxetine—Epistaxis—Doxorubicin—ovarian cancer	0.000446	0.000542	CcSEcCtD
Duloxetine—Visual impairment—Epirubicin—ovarian cancer	0.000443	0.000537	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000441	0.000535	CcSEcCtD
Duloxetine—Insomnia—Docetaxel—ovarian cancer	0.000438	0.000531	CcSEcCtD
Duloxetine—Paraesthesia—Docetaxel—ovarian cancer	0.000434	0.000527	CcSEcCtD
Duloxetine—Erythema multiforme—Epirubicin—ovarian cancer	0.000434	0.000527	CcSEcCtD
Duloxetine—Somnolence—Docetaxel—ovarian cancer	0.00043	0.000522	CcSEcCtD
Duloxetine—Eye disorder—Epirubicin—ovarian cancer	0.000429	0.000521	CcSEcCtD
Duloxetine—Tinnitus—Epirubicin—ovarian cancer	0.000428	0.000519	CcSEcCtD
Duloxetine—Haemoglobin—Doxorubicin—ovarian cancer	0.000427	0.000518	CcSEcCtD
Duloxetine—Flushing—Epirubicin—ovarian cancer	0.000426	0.000517	CcSEcCtD
Duloxetine—Cardiac disorder—Epirubicin—ovarian cancer	0.000426	0.000517	CcSEcCtD
Duloxetine—Dyspepsia—Docetaxel—ovarian cancer	0.000426	0.000516	CcSEcCtD
Duloxetine—Haemorrhage—Doxorubicin—ovarian cancer	0.000425	0.000515	CcSEcCtD
Duloxetine—Hepatitis—Doxorubicin—ovarian cancer	0.000425	0.000515	CcSEcCtD
Duloxetine—Hypoaesthesia—Doxorubicin—ovarian cancer	0.000423	0.000513	CcSEcCtD
Duloxetine—Pharyngitis—Doxorubicin—ovarian cancer	0.000422	0.000512	CcSEcCtD
Duloxetine—Decreased appetite—Docetaxel—ovarian cancer	0.000421	0.00051	CcSEcCtD
Duloxetine—Hypersensitivity—Paclitaxel—ovarian cancer	0.00042	0.00051	CcSEcCtD
Duloxetine—Urinary tract disorder—Doxorubicin—ovarian cancer	0.00042	0.000509	CcSEcCtD
Duloxetine—Oedema peripheral—Doxorubicin—ovarian cancer	0.000419	0.000508	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000418	0.000507	CcSEcCtD
Duloxetine—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000418	0.000507	CcSEcCtD
Duloxetine—Fatigue—Docetaxel—ovarian cancer	0.000417	0.000506	CcSEcCtD
Duloxetine—Angiopathy—Epirubicin—ovarian cancer	0.000417	0.000505	CcSEcCtD
Duloxetine—Urethral disorder—Doxorubicin—ovarian cancer	0.000417	0.000505	CcSEcCtD
Duloxetine—Immune system disorder—Epirubicin—ovarian cancer	0.000415	0.000503	CcSEcCtD
Duloxetine—Mediastinal disorder—Epirubicin—ovarian cancer	0.000414	0.000502	CcSEcCtD
Duloxetine—Pain—Docetaxel—ovarian cancer	0.000414	0.000502	CcSEcCtD
Duloxetine—Constipation—Docetaxel—ovarian cancer	0.000414	0.000502	CcSEcCtD
Duloxetine—Chills—Epirubicin—ovarian cancer	0.000412	0.0005	CcSEcCtD
Duloxetine—Arrhythmia—Epirubicin—ovarian cancer	0.00041	0.000498	CcSEcCtD
Duloxetine—Visual impairment—Doxorubicin—ovarian cancer	0.00041	0.000497	CcSEcCtD
Duloxetine—Asthenia—Paclitaxel—ovarian cancer	0.000409	0.000497	CcSEcCtD
Duloxetine—Alopecia—Epirubicin—ovarian cancer	0.000406	0.000492	CcSEcCtD
Duloxetine—Pruritus—Paclitaxel—ovarian cancer	0.000404	0.00049	CcSEcCtD
Duloxetine—Mental disorder—Epirubicin—ovarian cancer	0.000402	0.000488	CcSEcCtD
Duloxetine—Erythema multiforme—Doxorubicin—ovarian cancer	0.000402	0.000487	CcSEcCtD
Duloxetine—Malnutrition—Epirubicin—ovarian cancer	0.0004	0.000485	CcSEcCtD
Duloxetine—Erythema—Epirubicin—ovarian cancer	0.0004	0.000485	CcSEcCtD
Duloxetine—Feeling abnormal—Docetaxel—ovarian cancer	0.000399	0.000484	CcSEcCtD
Duloxetine—Eye disorder—Doxorubicin—ovarian cancer	0.000397	0.000482	CcSEcCtD
Duloxetine—Tinnitus—Doxorubicin—ovarian cancer	0.000396	0.000481	CcSEcCtD
Duloxetine—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000396	0.00048	CcSEcCtD
Duloxetine—Flushing—Doxorubicin—ovarian cancer	0.000394	0.000478	CcSEcCtD
Duloxetine—Cardiac disorder—Doxorubicin—ovarian cancer	0.000394	0.000478	CcSEcCtD
Duloxetine—Flatulence—Epirubicin—ovarian cancer	0.000394	0.000478	CcSEcCtD
Duloxetine—Tension—Epirubicin—ovarian cancer	0.000392	0.000476	CcSEcCtD
Duloxetine—Dysgeusia—Epirubicin—ovarian cancer	0.000392	0.000475	CcSEcCtD
Duloxetine—Diarrhoea—Paclitaxel—ovarian cancer	0.00039	0.000474	CcSEcCtD
Duloxetine—Nervousness—Epirubicin—ovarian cancer	0.000388	0.000471	CcSEcCtD
Duloxetine—Back pain—Epirubicin—ovarian cancer	0.000387	0.000469	CcSEcCtD
Duloxetine—Angiopathy—Doxorubicin—ovarian cancer	0.000386	0.000468	CcSEcCtD
Duloxetine—Muscle spasms—Epirubicin—ovarian cancer	0.000384	0.000466	CcSEcCtD
Duloxetine—Immune system disorder—Doxorubicin—ovarian cancer	0.000384	0.000466	CcSEcCtD
Duloxetine—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000383	0.000465	CcSEcCtD
Duloxetine—Abdominal pain—Docetaxel—ovarian cancer	0.000382	0.000464	CcSEcCtD
Duloxetine—Body temperature increased—Docetaxel—ovarian cancer	0.000382	0.000464	CcSEcCtD
Duloxetine—Chills—Doxorubicin—ovarian cancer	0.000381	0.000462	CcSEcCtD
Duloxetine—Arrhythmia—Doxorubicin—ovarian cancer	0.00038	0.00046	CcSEcCtD
Duloxetine—Dizziness—Paclitaxel—ovarian cancer	0.000377	0.000458	CcSEcCtD
Duloxetine—Vision blurred—Epirubicin—ovarian cancer	0.000377	0.000457	CcSEcCtD
Duloxetine—Alopecia—Doxorubicin—ovarian cancer	0.000376	0.000455	CcSEcCtD
Duloxetine—Mental disorder—Doxorubicin—ovarian cancer	0.000372	0.000452	CcSEcCtD
Duloxetine—Ill-defined disorder—Epirubicin—ovarian cancer	0.000371	0.00045	CcSEcCtD
Duloxetine—Malnutrition—Doxorubicin—ovarian cancer	0.00037	0.000449	CcSEcCtD
Duloxetine—Erythema—Doxorubicin—ovarian cancer	0.00037	0.000449	CcSEcCtD
Duloxetine—Anaemia—Epirubicin—ovarian cancer	0.00037	0.000448	CcSEcCtD
Duloxetine—Agitation—Epirubicin—ovarian cancer	0.000367	0.000446	CcSEcCtD
Duloxetine—Flatulence—Doxorubicin—ovarian cancer	0.000365	0.000442	CcSEcCtD
Duloxetine—Tension—Doxorubicin—ovarian cancer	0.000363	0.00044	CcSEcCtD
Duloxetine—Vomiting—Paclitaxel—ovarian cancer	0.000363	0.00044	CcSEcCtD
Duloxetine—Dysgeusia—Doxorubicin—ovarian cancer	0.000362	0.000439	CcSEcCtD
Duloxetine—Malaise—Epirubicin—ovarian cancer	0.000361	0.000437	CcSEcCtD
Duloxetine—Rash—Paclitaxel—ovarian cancer	0.00036	0.000436	CcSEcCtD
Duloxetine—Dermatitis—Paclitaxel—ovarian cancer	0.00036	0.000436	CcSEcCtD
Duloxetine—Nervousness—Doxorubicin—ovarian cancer	0.000359	0.000436	CcSEcCtD
Duloxetine—Vertigo—Epirubicin—ovarian cancer	0.000359	0.000436	CcSEcCtD
Duloxetine—Syncope—Epirubicin—ovarian cancer	0.000359	0.000435	CcSEcCtD
Duloxetine—Leukopenia—Epirubicin—ovarian cancer	0.000358	0.000434	CcSEcCtD
Duloxetine—Back pain—Doxorubicin—ovarian cancer	0.000358	0.000434	CcSEcCtD
Duloxetine—Headache—Paclitaxel—ovarian cancer	0.000358	0.000434	CcSEcCtD
Duloxetine—Hypersensitivity—Docetaxel—ovarian cancer	0.000356	0.000432	CcSEcCtD
Duloxetine—Muscle spasms—Doxorubicin—ovarian cancer	0.000356	0.000431	CcSEcCtD
Duloxetine—Palpitations—Epirubicin—ovarian cancer	0.000353	0.000429	CcSEcCtD
Duloxetine—Loss of consciousness—Epirubicin—ovarian cancer	0.000351	0.000426	CcSEcCtD
Duloxetine—Cough—Epirubicin—ovarian cancer	0.000349	0.000423	CcSEcCtD
Duloxetine—Vision blurred—Doxorubicin—ovarian cancer	0.000349	0.000423	CcSEcCtD
Duloxetine—Asthenia—Docetaxel—ovarian cancer	0.000347	0.000421	CcSEcCtD
Duloxetine—Convulsion—Epirubicin—ovarian cancer	0.000346	0.00042	CcSEcCtD
Duloxetine—Hypertension—Epirubicin—ovarian cancer	0.000345	0.000419	CcSEcCtD
Duloxetine—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000343	0.000416	CcSEcCtD
Duloxetine—Pruritus—Docetaxel—ovarian cancer	0.000342	0.000415	CcSEcCtD
Duloxetine—Anaemia—Doxorubicin—ovarian cancer	0.000342	0.000415	CcSEcCtD
Duloxetine—Chest pain—Epirubicin—ovarian cancer	0.00034	0.000413	CcSEcCtD
Duloxetine—Arthralgia—Epirubicin—ovarian cancer	0.00034	0.000413	CcSEcCtD
Duloxetine—Myalgia—Epirubicin—ovarian cancer	0.00034	0.000413	CcSEcCtD
Duloxetine—Agitation—Doxorubicin—ovarian cancer	0.00034	0.000412	CcSEcCtD
Duloxetine—Anxiety—Epirubicin—ovarian cancer	0.000339	0.000411	CcSEcCtD
Duloxetine—Nausea—Paclitaxel—ovarian cancer	0.000339	0.000411	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000338	0.00041	CcSEcCtD
Duloxetine—Discomfort—Epirubicin—ovarian cancer	0.000336	0.000408	CcSEcCtD
Duloxetine—Malaise—Doxorubicin—ovarian cancer	0.000334	0.000405	CcSEcCtD
Duloxetine—Dry mouth—Epirubicin—ovarian cancer	0.000333	0.000404	CcSEcCtD
Duloxetine—Vertigo—Doxorubicin—ovarian cancer	0.000332	0.000403	CcSEcCtD
Duloxetine—Syncope—Doxorubicin—ovarian cancer	0.000332	0.000402	CcSEcCtD
Duloxetine—Leukopenia—Doxorubicin—ovarian cancer	0.000331	0.000402	CcSEcCtD
Duloxetine—Diarrhoea—Docetaxel—ovarian cancer	0.000331	0.000401	CcSEcCtD
Duloxetine—Confusional state—Epirubicin—ovarian cancer	0.000329	0.000399	CcSEcCtD
Duloxetine—Protriptyline—ABCB1—ovarian cancer	0.000328	0.476	CrCbGaD
Duloxetine—Palpitations—Doxorubicin—ovarian cancer	0.000327	0.000397	CcSEcCtD
Duloxetine—Oedema—Epirubicin—ovarian cancer	0.000326	0.000396	CcSEcCtD
Duloxetine—Anaphylactic shock—Epirubicin—ovarian cancer	0.000326	0.000396	CcSEcCtD
Duloxetine—Loss of consciousness—Doxorubicin—ovarian cancer	0.000325	0.000394	CcSEcCtD
Duloxetine—Infection—Epirubicin—ovarian cancer	0.000324	0.000393	CcSEcCtD
Duloxetine—Cough—Doxorubicin—ovarian cancer	0.000323	0.000392	CcSEcCtD
Duloxetine—Shock—Epirubicin—ovarian cancer	0.000321	0.000389	CcSEcCtD
Duloxetine—Convulsion—Doxorubicin—ovarian cancer	0.000321	0.000389	CcSEcCtD
Duloxetine—Nervous system disorder—Epirubicin—ovarian cancer	0.00032	0.000388	CcSEcCtD
Duloxetine—Dizziness—Docetaxel—ovarian cancer	0.00032	0.000388	CcSEcCtD
Duloxetine—Thrombocytopenia—Epirubicin—ovarian cancer	0.000319	0.000387	CcSEcCtD
Duloxetine—Hypertension—Doxorubicin—ovarian cancer	0.000319	0.000387	CcSEcCtD
Duloxetine—Tachycardia—Epirubicin—ovarian cancer	0.000318	0.000386	CcSEcCtD
Duloxetine—Skin disorder—Epirubicin—ovarian cancer	0.000317	0.000384	CcSEcCtD
Duloxetine—Hyperhidrosis—Epirubicin—ovarian cancer	0.000315	0.000383	CcSEcCtD
Duloxetine—Chest pain—Doxorubicin—ovarian cancer	0.000315	0.000382	CcSEcCtD
Duloxetine—Myalgia—Doxorubicin—ovarian cancer	0.000315	0.000382	CcSEcCtD
Duloxetine—Arthralgia—Doxorubicin—ovarian cancer	0.000315	0.000382	CcSEcCtD
Duloxetine—Anxiety—Doxorubicin—ovarian cancer	0.000314	0.000381	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000313	0.000379	CcSEcCtD
Duloxetine—Discomfort—Doxorubicin—ovarian cancer	0.000311	0.000377	CcSEcCtD
Duloxetine—Anorexia—Epirubicin—ovarian cancer	0.000311	0.000377	CcSEcCtD
Duloxetine—Dry mouth—Doxorubicin—ovarian cancer	0.000308	0.000374	CcSEcCtD
Duloxetine—Vomiting—Docetaxel—ovarian cancer	0.000308	0.000373	CcSEcCtD
Duloxetine—Rash—Docetaxel—ovarian cancer	0.000305	0.00037	CcSEcCtD
Duloxetine—Dermatitis—Docetaxel—ovarian cancer	0.000305	0.00037	CcSEcCtD
Duloxetine—Confusional state—Doxorubicin—ovarian cancer	0.000304	0.000369	CcSEcCtD
Duloxetine—Headache—Docetaxel—ovarian cancer	0.000303	0.000368	CcSEcCtD
Duloxetine—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000302	0.000366	CcSEcCtD
Duloxetine—Oedema—Doxorubicin—ovarian cancer	0.000302	0.000366	CcSEcCtD
Duloxetine—Infection—Doxorubicin—ovarian cancer	0.0003	0.000364	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000297	0.000361	CcSEcCtD
Duloxetine—Shock—Doxorubicin—ovarian cancer	0.000297	0.00036	CcSEcCtD
Duloxetine—Nervous system disorder—Doxorubicin—ovarian cancer	0.000296	0.000359	CcSEcCtD
Duloxetine—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000296	0.000359	CcSEcCtD
Duloxetine—Insomnia—Epirubicin—ovarian cancer	0.000295	0.000358	CcSEcCtD
Duloxetine—Tachycardia—Doxorubicin—ovarian cancer	0.000295	0.000357	CcSEcCtD
Duloxetine—Skin disorder—Doxorubicin—ovarian cancer	0.000293	0.000356	CcSEcCtD
Duloxetine—Paraesthesia—Epirubicin—ovarian cancer	0.000293	0.000355	CcSEcCtD
Duloxetine—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000292	0.000354	CcSEcCtD
Duloxetine—Somnolence—Epirubicin—ovarian cancer	0.00029	0.000352	CcSEcCtD
Duloxetine—Anorexia—Doxorubicin—ovarian cancer	0.000288	0.000349	CcSEcCtD
Duloxetine—Nausea—Docetaxel—ovarian cancer	0.000287	0.000349	CcSEcCtD
Duloxetine—Dyspepsia—Epirubicin—ovarian cancer	0.000287	0.000348	CcSEcCtD
Duloxetine—Decreased appetite—Epirubicin—ovarian cancer	0.000284	0.000344	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000282	0.000342	CcSEcCtD
Duloxetine—Fatigue—Epirubicin—ovarian cancer	0.000281	0.000341	CcSEcCtD
Duloxetine—Constipation—Epirubicin—ovarian cancer	0.000279	0.000338	CcSEcCtD
Duloxetine—Pain—Epirubicin—ovarian cancer	0.000279	0.000338	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000275	0.000334	CcSEcCtD
Duloxetine—Insomnia—Doxorubicin—ovarian cancer	0.000273	0.000331	CcSEcCtD
Duloxetine—Paraesthesia—Doxorubicin—ovarian cancer	0.000271	0.000329	CcSEcCtD
Duloxetine—Feeling abnormal—Epirubicin—ovarian cancer	0.000269	0.000326	CcSEcCtD
Duloxetine—Somnolence—Doxorubicin—ovarian cancer	0.000268	0.000326	CcSEcCtD
Duloxetine—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000267	0.000324	CcSEcCtD
Duloxetine—Dyspepsia—Doxorubicin—ovarian cancer	0.000266	0.000322	CcSEcCtD
Duloxetine—Decreased appetite—Doxorubicin—ovarian cancer	0.000262	0.000318	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000261	0.000316	CcSEcCtD
Duloxetine—Fatigue—Doxorubicin—ovarian cancer	0.00026	0.000316	CcSEcCtD
Duloxetine—Urticaria—Epirubicin—ovarian cancer	0.000259	0.000314	CcSEcCtD
Duloxetine—Pain—Doxorubicin—ovarian cancer	0.000258	0.000313	CcSEcCtD
Duloxetine—Constipation—Doxorubicin—ovarian cancer	0.000258	0.000313	CcSEcCtD
Duloxetine—Abdominal pain—Epirubicin—ovarian cancer	0.000258	0.000313	CcSEcCtD
Duloxetine—Body temperature increased—Epirubicin—ovarian cancer	0.000258	0.000313	CcSEcCtD
Duloxetine—Feeling abnormal—Doxorubicin—ovarian cancer	0.000249	0.000302	CcSEcCtD
Duloxetine—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000247	0.000299	CcSEcCtD
Duloxetine—Hypersensitivity—Epirubicin—ovarian cancer	0.00024	0.000292	CcSEcCtD
Duloxetine—Urticaria—Doxorubicin—ovarian cancer	0.00024	0.000291	CcSEcCtD
Duloxetine—Abdominal pain—Doxorubicin—ovarian cancer	0.000239	0.000289	CcSEcCtD
Duloxetine—Body temperature increased—Doxorubicin—ovarian cancer	0.000239	0.000289	CcSEcCtD
Duloxetine—Asthenia—Epirubicin—ovarian cancer	0.000234	0.000284	CcSEcCtD
Duloxetine—Pruritus—Epirubicin—ovarian cancer	0.000231	0.00028	CcSEcCtD
Duloxetine—Fluoxetine—ABCB1—ovarian cancer	0.000224	0.325	CrCbGaD
Duloxetine—Diarrhoea—Epirubicin—ovarian cancer	0.000223	0.000271	CcSEcCtD
Duloxetine—Hypersensitivity—Doxorubicin—ovarian cancer	0.000222	0.00027	CcSEcCtD
Duloxetine—Asthenia—Doxorubicin—ovarian cancer	0.000217	0.000263	CcSEcCtD
Duloxetine—Dizziness—Epirubicin—ovarian cancer	0.000216	0.000262	CcSEcCtD
Duloxetine—Pruritus—Doxorubicin—ovarian cancer	0.000214	0.000259	CcSEcCtD
Duloxetine—Vomiting—Epirubicin—ovarian cancer	0.000207	0.000252	CcSEcCtD
Duloxetine—Diarrhoea—Doxorubicin—ovarian cancer	0.000207	0.000251	CcSEcCtD
Duloxetine—Rash—Epirubicin—ovarian cancer	0.000206	0.00025	CcSEcCtD
Duloxetine—Dermatitis—Epirubicin—ovarian cancer	0.000206	0.000249	CcSEcCtD
Duloxetine—Headache—Epirubicin—ovarian cancer	0.000204	0.000248	CcSEcCtD
Duloxetine—Dizziness—Doxorubicin—ovarian cancer	0.0002	0.000242	CcSEcCtD
Duloxetine—Nausea—Epirubicin—ovarian cancer	0.000194	0.000235	CcSEcCtD
Duloxetine—Vomiting—Doxorubicin—ovarian cancer	0.000192	0.000233	CcSEcCtD
Duloxetine—Rash—Doxorubicin—ovarian cancer	0.00019	0.000231	CcSEcCtD
Duloxetine—Dermatitis—Doxorubicin—ovarian cancer	0.00019	0.000231	CcSEcCtD
Duloxetine—Headache—Doxorubicin—ovarian cancer	0.000189	0.000229	CcSEcCtD
Duloxetine—Nausea—Doxorubicin—ovarian cancer	0.000179	0.000218	CcSEcCtD
Duloxetine—Propranolol—ABCB1—ovarian cancer	0.000137	0.198	CrCbGaD
Duloxetine—NPY1R—Signaling by GPCR—IL6—ovarian cancer	5.31e-05	0.000675	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HDAC6—ovarian cancer	5.28e-05	0.000672	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—PIK3CG—ovarian cancer	5.21e-05	0.000663	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PPP2R1A—ovarian cancer	5.21e-05	0.000662	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—ovarian cancer	5.21e-05	0.000662	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CCND1—ovarian cancer	5.2e-05	0.000661	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PARP1—ovarian cancer	5.15e-05	0.000655	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CTNNB1—ovarian cancer	5.15e-05	0.000655	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—MMP9—ovarian cancer	5.05e-05	0.000642	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—PTEN—ovarian cancer	5.02e-05	0.000638	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—CXCL8—ovarian cancer	5e-05	0.000636	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—ovarian cancer	4.98e-05	0.000634	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—IL6ST—ovarian cancer	4.93e-05	0.000627	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYTB—ovarian cancer	4.91e-05	0.000624	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—AKT1—ovarian cancer	4.9e-05	0.000623	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—ovarian cancer	4.89e-05	0.000622	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—PIK3CG—ovarian cancer	4.74e-05	0.000602	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—YAP1—ovarian cancer	4.67e-05	0.000594	CbGpPWpGaD
Duloxetine—SLC6A3—Neuronal System—HRAS—ovarian cancer	4.65e-05	0.000591	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HDAC6—ovarian cancer	4.59e-05	0.000583	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—PIK3CD—ovarian cancer	4.58e-05	0.000583	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—XIAP—ovarian cancer	4.58e-05	0.000582	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—VEGFA—ovarian cancer	4.54e-05	0.000577	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PPP2R1A—ovarian cancer	4.52e-05	0.000575	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—ovarian cancer	4.52e-05	0.000575	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—STAT3—ovarian cancer	4.49e-05	0.000571	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—NRAS—ovarian cancer	4.48e-05	0.00057	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SMARCA4—ovarian cancer	4.46e-05	0.000567	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	4.46e-05	0.000567	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—EREG—ovarian cancer	4.36e-05	0.000554	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—CXCL8—ovarian cancer	4.35e-05	0.000552	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—ovarian cancer	4.33e-05	0.00055	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PPP1CC—ovarian cancer	4.29e-05	0.000546	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—BRIP1—ovarian cancer	4.29e-05	0.000546	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—MAPK3—ovarian cancer	4.29e-05	0.000546	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PPP2R1A—ovarian cancer	4.18e-05	0.000531	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—MYC—ovarian cancer	4.17e-05	0.000531	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—PIK3CD—ovarian cancer	4.16e-05	0.000529	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYTB—ovarian cancer	4.16e-05	0.000529	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—MAPK1—ovarian cancer	4.08e-05	0.000519	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—EGFR—ovarian cancer	4.08e-05	0.000519	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PGR—ovarian cancer	4.08e-05	0.000519	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	4.06e-05	0.000517	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—YAP1—ovarian cancer	4.06e-05	0.000516	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—PIK3CB—ovarian cancer	4e-05	0.000508	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—XIAP—ovarian cancer	3.98e-05	0.000506	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SMARCA4—ovarian cancer	3.88e-05	0.000493	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—KRAS—ovarian cancer	3.86e-05	0.00049	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—PIK3CG—ovarian cancer	3.84e-05	0.000488	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—CXCL8—ovarian cancer	3.84e-05	0.000488	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PARP1—ovarian cancer	3.79e-05	0.000482	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—EREG—ovarian cancer	3.78e-05	0.000481	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—IL2—ovarian cancer	3.67e-05	0.000467	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—BRIP1—ovarian cancer	3.63e-05	0.000462	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PPP1CC—ovarian cancer	3.63e-05	0.000462	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL6ST—ovarian cancer	3.63e-05	0.000461	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—PIK3CB—ovarian cancer	3.63e-05	0.000461	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PGR—ovarian cancer	3.54e-05	0.000451	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—PIK3CA—ovarian cancer	3.54e-05	0.00045	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PIK3CG—ovarian cancer	3.49e-05	0.000443	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CXCL8—ovarian cancer	3.49e-05	0.000443	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TP53—ovarian cancer	3.43e-05	0.000436	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—PIK3CD—ovarian cancer	3.38e-05	0.000429	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PIK3CG—ovarian cancer	3.33e-05	0.000424	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—IL2—ovarian cancer	3.33e-05	0.000424	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TERT—ovarian cancer	3.32e-05	0.000422	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PARP1—ovarian cancer	3.29e-05	0.000419	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—HRAS—ovarian cancer	3.28e-05	0.000417	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL6ST—ovarian cancer	3.15e-05	0.000401	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—IL6—ovarian cancer	3.14e-05	0.000399	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PPP2R1A—ovarian cancer	3.08e-05	0.000391	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CAV1—ovarian cancer	3.07e-05	0.00039	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PIK3CD—ovarian cancer	3.07e-05	0.00039	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PIK3CG—ovarian cancer	3.03e-05	0.000385	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—ESR1—ovarian cancer	2.96e-05	0.000376	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—PIK3CB—ovarian cancer	2.94e-05	0.000374	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PIK3CD—ovarian cancer	2.93e-05	0.000373	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL6ST—ovarian cancer	2.91e-05	0.00037	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—AKT1—ovarian cancer	2.89e-05	0.000368	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—YAP1—ovarian cancer	2.88e-05	0.000366	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CXCL8—ovarian cancer	2.83e-05	0.00036	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—APC—ovarian cancer	2.8e-05	0.000356	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3CG—ovarian cancer	2.8e-05	0.000356	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—NRAS—ovarian cancer	2.8e-05	0.000356	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—IL2—ovarian cancer	2.7e-05	0.000344	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—MAPK3—ovarian cancer	2.68e-05	0.000341	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PPP2R1A—ovarian cancer	2.67e-05	0.00034	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PIK3CB—ovarian cancer	2.67e-05	0.00034	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PIK3CD—ovarian cancer	2.66e-05	0.000338	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	2.65e-05	0.000337	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CXCL8—ovarian cancer	2.57e-05	0.000326	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PIK3CB—ovarian cancer	2.56e-05	0.000325	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—MAPK1—ovarian cancer	2.55e-05	0.000324	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—EGFR—ovarian cancer	2.55e-05	0.000324	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3CD—ovarian cancer	2.46e-05	0.000313	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CXCL8—ovarian cancer	2.46e-05	0.000312	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL2—ovarian cancer	2.45e-05	0.000312	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TERT—ovarian cancer	2.45e-05	0.000311	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—YAP1—ovarian cancer	2.44e-05	0.00031	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—PIK3CA—ovarian cancer	2.44e-05	0.00031	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	2.41e-05	0.000307	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—KRAS—ovarian cancer	2.41e-05	0.000306	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—IL2—ovarian cancer	2.35e-05	0.000298	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—FASN—ovarian cancer	2.35e-05	0.000298	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PIK3CB—ovarian cancer	2.32e-05	0.000295	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SLC5A5—ovarian cancer	2.31e-05	0.000293	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CAV1—ovarian cancer	2.26e-05	0.000288	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CXCL8—ovarian cancer	2.23e-05	0.000284	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SLC2A1—ovarian cancer	2.23e-05	0.000283	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—PIK3CA—ovarian cancer	2.21e-05	0.000281	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ESR1—ovarian cancer	2.18e-05	0.000277	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—ERBB2—ovarian cancer	2.17e-05	0.000276	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL6ST—ovarian cancer	2.14e-05	0.000273	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MTOR—ovarian cancer	2.14e-05	0.000273	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3CB—ovarian cancer	2.14e-05	0.000273	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP1B1—ovarian cancer	2.14e-05	0.000272	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL2—ovarian cancer	2.13e-05	0.000271	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TERT—ovarian cancer	2.12e-05	0.00027	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	2.12e-05	0.00027	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—APC—ovarian cancer	2.06e-05	0.000262	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CG—ovarian cancer	2.06e-05	0.000262	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—NRAS—ovarian cancer	2.06e-05	0.000262	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CXCL8—ovarian cancer	2.06e-05	0.000262	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—HRAS—ovarian cancer	2.05e-05	0.00026	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CDKN1B—ovarian cancer	2.01e-05	0.000256	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—AKT1—ovarian cancer	1.99e-05	0.000253	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—FASN—ovarian cancer	1.99e-05	0.000253	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—MAPK3—ovarian cancer	1.97e-05	0.000251	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CASP3—ovarian cancer	1.97e-05	0.000251	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL2—ovarian cancer	1.97e-05	0.00025	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CAV1—ovarian cancer	1.96e-05	0.00025	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—IL6—ovarian cancer	1.96e-05	0.000249	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SLC5A5—ovarian cancer	1.95e-05	0.000249	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCND1—ovarian cancer	1.92e-05	0.000244	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CTNNB1—ovarian cancer	1.9e-05	0.000242	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	1.89e-05	0.000241	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ESR1—ovarian cancer	1.89e-05	0.000241	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SLC2A1—ovarian cancer	1.89e-05	0.00024	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—MAPK1—ovarian cancer	1.88e-05	0.000239	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—EGFR—ovarian cancer	1.88e-05	0.000239	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MMP9—ovarian cancer	1.86e-05	0.000237	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL6ST—ovarian cancer	1.86e-05	0.000237	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PTEN—ovarian cancer	1.85e-05	0.000236	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.85e-05	0.000235	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CD—ovarian cancer	1.81e-05	0.00023	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP1B1—ovarian cancer	1.81e-05	0.00023	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—AKT1—ovarian cancer	1.81e-05	0.00023	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—PIK3CA—ovarian cancer	1.79e-05	0.000228	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CG—ovarian cancer	1.79e-05	0.000227	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—APC—ovarian cancer	1.79e-05	0.000227	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—NRAS—ovarian cancer	1.79e-05	0.000227	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—KRAS—ovarian cancer	1.77e-05	0.000225	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ABCB1—ovarian cancer	1.76e-05	0.000224	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—TYMS—ovarian cancer	1.73e-05	0.00022	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—MAPK3—ovarian cancer	1.71e-05	0.000218	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—VEGFA—ovarian cancer	1.67e-05	0.000213	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—STAT3—ovarian cancer	1.66e-05	0.000211	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NRAS—ovarian cancer	1.65e-05	0.00021	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—MAPK1—ovarian cancer	1.63e-05	0.000207	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—EGFR—ovarian cancer	1.63e-05	0.000207	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PIK3CA—ovarian cancer	1.63e-05	0.000207	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PPP2R1A—ovarian cancer	1.61e-05	0.000204	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ERBB2—ovarian cancer	1.6e-05	0.000203	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.6e-05	0.000203	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MAPK3—ovarian cancer	1.58e-05	0.000201	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CB—ovarian cancer	1.58e-05	0.000201	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MTOR—ovarian cancer	1.58e-05	0.000201	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CD—ovarian cancer	1.57e-05	0.0002	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PIK3CA—ovarian cancer	1.56e-05	0.000198	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—KRAS—ovarian cancer	1.54e-05	0.000196	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MYC—ovarian cancer	1.54e-05	0.000196	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CXCL8—ovarian cancer	1.52e-05	0.000193	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—HRAS—ovarian cancer	1.51e-05	0.000192	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MAPK1—ovarian cancer	1.51e-05	0.000191	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—EGFR—ovarian cancer	1.51e-05	0.000191	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ABCB1—ovarian cancer	1.49e-05	0.00019	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CDKN1B—ovarian cancer	1.48e-05	0.000188	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—AKT1—ovarian cancer	1.47e-05	0.000186	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—TYMS—ovarian cancer	1.46e-05	0.000186	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CASP3—ovarian cancer	1.45e-05	0.000185	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL2—ovarian cancer	1.45e-05	0.000184	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL6—ovarian cancer	1.44e-05	0.000183	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—KRAS—ovarian cancer	1.42e-05	0.000181	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PIK3CA—ovarian cancer	1.41e-05	0.00018	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCND1—ovarian cancer	1.41e-05	0.00018	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CTNNB1—ovarian cancer	1.4e-05	0.000178	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CAV1—ovarian cancer	1.39e-05	0.000177	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ERBB2—ovarian cancer	1.39e-05	0.000177	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MMP9—ovarian cancer	1.37e-05	0.000174	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CB—ovarian cancer	1.37e-05	0.000174	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MTOR—ovarian cancer	1.37e-05	0.000174	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PTEN—ovarian cancer	1.36e-05	0.000173	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—AKT1—ovarian cancer	1.33e-05	0.000169	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CXCL8—ovarian cancer	1.32e-05	0.000167	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—HRAS—ovarian cancer	1.31e-05	0.000166	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3CA—ovarian cancer	1.31e-05	0.000166	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CDKN1B—ovarian cancer	1.29e-05	0.000164	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—AKT1—ovarian cancer	1.27e-05	0.000162	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CG—ovarian cancer	1.27e-05	0.000161	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TP53—ovarian cancer	1.26e-05	0.000161	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CASP3—ovarian cancer	1.26e-05	0.00016	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL2—ovarian cancer	1.26e-05	0.00016	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL6—ovarian cancer	1.25e-05	0.000159	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—VEGFA—ovarian cancer	1.23e-05	0.000157	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCND1—ovarian cancer	1.23e-05	0.000156	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—STAT3—ovarian cancer	1.22e-05	0.000155	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NRAS—ovarian cancer	1.22e-05	0.000155	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CTNNB1—ovarian cancer	1.22e-05	0.000155	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HRAS—ovarian cancer	1.21e-05	0.000154	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MMP9—ovarian cancer	1.19e-05	0.000151	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PTEN—ovarian cancer	1.18e-05	0.000151	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CAV1—ovarian cancer	1.18e-05	0.00015	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MAPK3—ovarian cancer	1.17e-05	0.000148	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL6—ovarian cancer	1.16e-05	0.000147	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—AKT1—ovarian cancer	1.16e-05	0.000147	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MYC—ovarian cancer	1.13e-05	0.000144	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.13e-05	0.000143	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CD—ovarian cancer	1.11e-05	0.000142	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MAPK1—ovarian cancer	1.11e-05	0.000141	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—EGFR—ovarian cancer	1.11e-05	0.000141	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CG—ovarian cancer	1.07e-05	0.000137	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—VEGFA—ovarian cancer	1.07e-05	0.000136	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—AKT1—ovarian cancer	1.07e-05	0.000136	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—STAT3—ovarian cancer	1.06e-05	0.000135	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NRAS—ovarian cancer	1.06e-05	0.000134	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—KRAS—ovarian cancer	1.05e-05	0.000133	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MAPK3—ovarian cancer	1.01e-05	0.000129	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MYC—ovarian cancer	9.84e-06	0.000125	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CB—ovarian cancer	9.72e-06	0.000124	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MAPK1—ovarian cancer	9.63e-06	0.000122	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—EGFR—ovarian cancer	9.63e-06	0.000122	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CA—ovarian cancer	9.62e-06	0.000122	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CD—ovarian cancer	9.45e-06	0.00012	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TP53—ovarian cancer	9.31e-06	0.000118	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—KRAS—ovarian cancer	9.1e-06	0.000116	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HRAS—ovarian cancer	8.9e-06	0.000113	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL6—ovarian cancer	8.52e-06	0.000108	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PTEN—ovarian cancer	8.4e-06	0.000107	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CA—ovarian cancer	8.36e-06	0.000106	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CB—ovarian cancer	8.23e-06	0.000105	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TP53—ovarian cancer	8.08e-06	0.000103	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AKT1—ovarian cancer	7.86e-06	0.0001	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HRAS—ovarian cancer	7.73e-06	9.83e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL6—ovarian cancer	7.4e-06	9.41e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PTEN—ovarian cancer	7.11e-06	9.05e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AKT1—ovarian cancer	6.83e-06	8.68e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CA—ovarian cancer	5.92e-06	7.53e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CA—ovarian cancer	5.02e-06	6.38e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—AKT1—ovarian cancer	4.84e-06	6.15e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—AKT1—ovarian cancer	4.1e-06	5.21e-05	CbGpPWpGaD
